Probiotics for the Prevention of Antibiotic-Associated Diarrhea

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Kiungo kimehifadhiwa kwenye clipboard

HaliKuachishwa

Wadhamini

The Hospital for Sick Children

Washirika

McMaster University

JARIBIO LA KLINIKI: NCT02817165

BioSeek: nct02817165

Maneno muhimu

Kikemikali

In North America, one of the most common reasons for hospitalization in previously healthy children is for the treatment of infections with antibiotics. This study will determine if, in previously healthy children hospitalized and prescribed intravenous (IV) antibiotics, the co-administration of a probiotic milk product containing good bacteria, is safe and effective for reducing AAD, as compared to a placebo (identical appearing milk product). This will be a two-center, randomized, masked, placebo-controlled clinical trial. The results of this study will help inform clinicians and families on the use of probiotics in the prevention of AAD, a common side effect of antibiotic use among hospitalized children.

Maelezo

A two-centred randomized, multi-blind (i.e. patients, caregivers, data collectors, outcome assessors, data managers and analysts), placebo-controlled clinical trial intended to evaluate the efficacy and safety of Bio-K+ (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2) in the prevention of AAD in hospitalized children 1 year to 17 years of age administered IV antibiotics.

Tarehe

Imethibitishwa Mwisho:	03/31/2018
Iliyowasilishwa Kwanza:	04/11/2016
Uandikishaji uliokadiriwa Uliwasilishwa:	06/24/2016
Iliyotumwa Kwanza:	06/28/2016
Sasisho la Mwisho Liliwasilishwa:	04/15/2018
Sasisho la Mwisho Lilichapishwa:	04/17/2018
Tarehe halisi ya kuanza kwa masomo:	10/31/2016
Tarehe ya Kukamilisha Msingi iliyokadiriwa:	09/30/2017
Tarehe ya Kukamilisha Utafiti:	12/31/2017

Hali au ugonjwa

Acute Diarrhea

Uingiliaji / matibabu

Dietary Supplement: Probiotic (BioK+)

Other: Placebo

Awamu

Vikundi vya Arm

Mkono	Uingiliaji / matibabu
Experimental: Probiotic (BioK+) Children will receive 10-40 billion CFUs/day of Bio-K+ (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2), with dose based on their weight. The product will be administered as a strawberry flavored tub of milk.	Dietary Supplement: Probiotic (BioK+) Probiotic (BioK+) with 3 stains of Lactobacillus
Placebo Comparator: Placebo Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.	Other: Placebo Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.

Vigezo vya Kustahiki

Zama zinazostahiki Kujifunza	1 Year Kwa 1 Year
Jinsia Inastahiki Kujifunza	All
Hupokea Wajitolea wa Afya	Ndio
Vigezo	Inclusion Criteria: 1. Participants will be children aged 1 year to 17 years admitted to the General Pediatric inpatient unit at The Hospital for Sick Children (Site 1) or McMaster Children's Hospital (Site 2). 2. Participants will be prescribed IV antibiotics with a planned duration of 1 or more days, and a total course of both IV and oral antibiotics, if applicable, of no more than 28 days. 3. Parent (if parent-report) or patient (if patient-report) is able to communicate in English (read, write, speak). Exclusion Criteria: 1. Parental or patient (e.g. child > 12 years old) report of current diarrhea, diarrhea within the last week. 2. Lactose intolerance. 3. Allergies to strawberry, dried citrus pulp, or any other components of the study product. 4. Immuno-compromised patients or those on immunosuppressive agents (e.g. heart or kidney transplant, complex care, sickle cell disease, chemotherapy agents, oral prednisone). 5. Patients with known or potentially compromised gut integrity (e.g. short gut, Inflammatory Bowel Disease, Celiac disease, Irritable Bowel Syndrome, nasogastric, nasojejunal or gastrostomy tube). 6. Children with serious and/or unstable medical conditions (e.g. diabetes, cardiovascular, renal, lung, psychiatric illness, bleeding disorders, etc.). 7. Children admitted to a medical or surgical subspecialty unit. 8. Patients enrolled in another study. 9. Patients previously randomized to this study. 10. Patient is pregnant.

Matokeo

Hatua za Matokeo ya Msingi

1. Incidence of antibiotic-associated diarrhea (AAD) [2 weeks after antibiotic + probiotic completion]

The investigators will employ a questionnaire addressing Pediatric Acute Diarrhea (qPAD), a measure of diarrhea involving the assessment of stool frequency and consistency for each bowel movement. To measure consistency, the qPAD contains a stool consistency classification system. Our registered sample size is based on pilot data from The Hospital for Sick Children indicating that the incidence of AAD is 33% (95% CI 23% to 43%) according to the qPAD. Given an estimated baseline AAD risk of 32.9% and a 48% relative risk reduction in AAD (Johnston et al, Cochrane Library, 2011), a randomized trial with 80% power and a 2-sided alpha of 0.05 comparing Bio-K+ with placebo would require a total sample size of 118 patients per group (236 total).

2. Incidence of antibiotic-associated diarrhea (AAD), global impression [2 weeks after antibiotic + probiotic completion]

Given that parents have knowledge of the child's typical bowel movements per day, the investigators will also employ a Global Rating Scale for diarrhea (GRSd), using a 0 to 4 scale (0 = no diarrhea, 1 = mild diarrhea, 2 = moderate diarrhea, 3 = severe diarrhea, 4 = worse imaginable diarrhea). The investigators will ask participants to select values based on diarrhea severity, which is a combination of stool frequency and consistency over 24 hours. Our registered sample size is based on the incidence of AAD (33%; 95% CI 23% to 43%) according to the qPAD. However, the incidence of AAD according to GRSd is 23%, which corresponds to the lower bound of the 95% CI for the qPAD. The investigators are currently applying for additional peer-reviewed funds. If these funds are obtained the investigators will power the trial based GRSd, a more conservative AAD incidence (23%). The investigators will also power the trial for a smaller treatment effect (39% relative risk reduction).

Hatua za Matokeo ya Sekondari

1. Severity of AAD [2 weeks after antibiotic completion]

The investigators will assess severity using the qPAD and the investigators will employ definitions for diarrhea from the Canadian Nosocomial Infection Surveillance Program, modified for use in children, defined as: severe: ≥6 loose/unformed/liquid stools; moderate: ≥3 loose/unformed/liquid stools; mild: a change in stooling pattern to 1-2 loose/unformed/liquid stools daily (Gravel 2007). The investigators will classify severity according to the 24-hour period with the highest degree of severity.

2. Adverse events [2 weeks after antibiotic completion]

Incidence of mild (e.g. self-resolving), moderate (e.g. those that warrant medical evaluation) and serious (e.g. those that warrant continued hospitalization) adverse events based on criteria adopted by the National Institute of Health common terminology criteria for adverse events (NIH severity) will be evaluated.

3. Duration of AAD [2 weeks after antibiotic completion]

The investigators will measure duration of AAD using a definition of diarrhea resolution (diarrhea offset) developed based on a systematic review of 138 trials of Pediatric Acute Diarrhea, and Delphi consensus with a panel of experts in pediatrics, clinical gastroenterology and measurement (Johnston BC et al. Pediatrics 2010; Jul;126(1):e222-31; Johnston BC et al. Symposium Probio, Quebec City, Canada, 2015). For children up to 17 years of age, acute diarrhea typically lasts less than 7 days and not longer than 14 days and resolution is marked by production of 2 consecutive normal stools (i.e. "soft and formed" or "hard and formed") stool or; production of one normal stool followed by 12 hours with no stool production or; normal stool production (or no stool production) for a period of 24 hours.